Zolbetuximab treatment in metastatic gastric cancer

In a placebo-controlled, double-blind, phase III trial, 565 patients with CLDN18.2+HER2– locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (previously untreated) were randomly assigned to receive zolbetuximab plus mFOLFOX6 or placebo plus mFOLFOX6. Progression-free survival was prolonged in the zolbetuximab group compared with placebo (10.61 months, 95% CI 8.90–12.48 and 8.67 months, 95% CI 8.21–10.28, respectively). In addition, zolbetuximab treatment reduced the risk of death compared with placebo (HR 0.75, 95% CI 0.60–0.94; P = 0.0053).

留言 (0)

沒有登入
gif